Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label Carboplatin. Show all posts
Showing posts with label Carboplatin. Show all posts
Tuesday, May 01, 2012

paywalled: Epigenetic Resensitization to Platinum in Ovarian Cancer (low-dose decitabine/carboplatin)

›
Epigenetic Resensitization to Platinum in Ovarian Cancer       "Together, the results of this study suggest that low-dose decitabine...

Medscape: Bevacizumab Benefits Patients With Recurrent Ovarian Cancer (bevacizumab plus carboplatin and gemcitabine followed by bevacizumab)

›
Bevacizumab Benefits Patients With Recurrent Ovarian Cancer
Wednesday, April 25, 2012

Add-on bevacizumab slows progression of recurrent ovarian cancer - - ModernMedicine

›
Add-on bevacizumab slows progression of recurrent ovarian cancer - - ModernMedicine (from Reuters) ".... Dr. Aghajanian and colleagu...
Tuesday, April 24, 2012

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids - Full Text View - ClinicalTrials.gov

›
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids - Full Text View - ClinicalTrials.gov This study is currently recruitin...
Saturday, April 21, 2012

abstract: Effects on the immune system and toxicity of carboplatin/paclitaxel combination chemotherapy in patients with stage III-IV ovarian and non small cell lung cancer and its role in survival and toxicity.

›
  Effects on the immune system and toxicity of carboplatin/paclitaxel combination chemotherapy in patients with stage III-IV ovarian and no...
Friday, April 06, 2012

abstract: A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study

›
A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, ...
Wednesday, March 21, 2012

abstract: Regimens with intraperitoneal cisplatin plus intravenuous cyclophosphamide and intraperitoneal carboplatin plus intravenuous cyclophosphamide are equally effective in second line intraperitoneal chemotherapy for advanced ovarian cancer.

›
Regimens with intraperitoneal cisplatin plus intravenuous cyclophosphamide and intraperitoneal carboplatin plus intravenuous cyclophosphamid...
Tuesday, March 20, 2012

abstract: Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer

›
Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. Abstract OBJECTIVE:  To identi...
Sunday, March 11, 2012

A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

›
A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal...
Friday, February 17, 2012

abstract: Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors (including OC)

›
Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors. Investigational new Drug...
Wednesday, February 01, 2012

abstract: Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial

›
Background: In the CALYPSO trial, carboplatin–pegylated liposomal doxorubicin (CD) demonstrated superior therapeutic index versus carbopl...
Wednesday, January 18, 2012

A Risk-Adapted Strategy of Adjuvant Paclitaxel/Carboplatin in Early-Stage Ovarian Cancer: Time-Dependent Effect of 4 versus 6 Cycles on Outcome.

›
Abstract Objective : We investigated the efficacy of risk-adapted adjuvant paclitaxel/carboplatin chemotherapy in early-stage ovarian c...
Tuesday, January 10, 2012

currently recruiting: Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial - Full Text View - ClinicalTrials.gov

›
Tuesday, January 03, 2012

Intravenous/Intraperitoneal Paclitaxel and Intraperitoneal C... : International Journal of Gynecological Cancer

›
Objective: This study aimed to evaluate intravenous (IV)/intraperitoneal (IP) paclitaxel and IP carboplatin (TCipTip therapy) feasibility...

Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer

›
  Objectives:  The purpose of this study was to assess the response rate, toxicity, progression-free survival, and overall survival in a s...
Thursday, December 29, 2011

A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

›
Highlights ► The maximum tolerated dose and feasibility of IV and IP chemotherapy was assessed. ► The dose limiting toxicity rate f...
Monday, August 08, 2011

Combination of two drugs (carboplatin/decitabine) 'can treat ovarian cancer' | International Federation of Gynecology and Obstetrics

›
Decitabine (duh-sye-tuh-bean) Trade/other name(s): Dacogen "...Experts from Indiana University (IU) noted that carboplat...
Monday, July 11, 2011

Abstract/full free access: Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/ refractory epithelial ovarian cancer

›
Saturday, May 28, 2011

abstract: Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer

›
CONCLUSIONS: Combined weekly cDC ( concurrent docetaxel and carboplatin ) appeared to be cost-effective compared with sDC ( sequential ...
Monday, March 14, 2011

PharmaLive: Topotarget Announces Updates on Belinostat in Two Clinical Trials - NSCLC and Ovarian Cancer (negative study ovarian/Belinostat/Carboplatin)

›
Ovarian cancer – GOG 0126-T (NCI-driven study) Preliminary analysis of GOG 0126-T trial has not shown enough activity to enter into second...